FDA Approves ATOVAQUONE — Bionpharma Inc.
Bionpharma Inc. announced the approval of the generic drug atovaquone, allowing the company to enter new markets and strengthen its portfolio of accessible therapies for blood and brain parasites. The clearance is expected to improve supply chain stability for manufacturers and reduce costs for patients requiring oral treatments with short shelf lives.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed